|
業務類別
|
Biotechnology |
|
業務概覽
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
| 公司地址
| 5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608 |
| 電話號碼
| +1 510 925-2492 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kyvernatx.com |
| 員工數量
| 112 |
| Mr. Warner Weston Biddle |
Chief Executive Officer and Director |
美元 182.29K |
14/04/2025 |
| Mr. Mayobanex Pujols |
Chief Technology Officer |
-- |
03/02/2026 |
| Dr. Marc Grasso, M.D. |
Chief Financial Officer and Principal Accounting Officer |
-- |
30/06/2025 |
| Dr. Naji H. Gehchan, M.D. |
Chief Medical and Development Officer |
-- |
14/04/2025 |
|
|
| Dr. Beth C. Seidenberg,M.D. |
Independent Director |
14/04/2025 |
| Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D. |
Independent Director |
14/04/2025 |
| Mr. Mert Aktar |
Independent Director |
14/04/2025 |
| Mr. Warner Weston Biddle |
Chief Executive Officer and Director |
14/04/2025 |
| Ms. Christi Shaw |
Chairman of the Board |
12/01/2026 |
| Mr. Daniel K. Spiegelman |
Independent Director |
14/04/2025 |
| Mr. Ian T. Clark |
Director |
12/01/2026 |
| Mr. Andrew Miller, Pd.D |
Director |
24/02/2026 |
| Mr. Sravan Emany |
Director |
24/02/2026 |
|
|
|
|
